Percutaneous Epididymal Sperm Aspiration (PESA) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Percutaneous Epididymal Sperm Aspiration (PESA) is a minimally invasive, outpatient sperm retrieval procedure used in the management of obstructive azoospermia (OA) — a condition where the testes produce sperm normally but the ductal system between the epididymis and urethra is blocked or congenitally absent. PESA enables men with this condition to father biological children through in vitro fertilisation using Intracytoplasmic Sperm Injection (ICSI).

First described by Shrivastav and colleagues in 1994, PESA has become one of the most widely practised surgical sperm retrieval techniques worldwide, valued for its simplicity, low complication rate, and high success rate in appropriately selected patients. The procedure requires no surgical incision, no operating microscope, no general anaesthesia, and can be performed in a standard outpatient clinic equipped for minor procedures — making it far more accessible than microsurgical alternatives.

PESA is performed by passing a fine-gauge needle (typically 23G) percutaneously through the scrotal skin into the epididymal head (caput) or body (corpus). Gentle negative pressure aspirates tubular fluid containing sperm, which is immediately processed by an embryologist. Retrieved sperm can be used fresh on the same day for ICSI or cryopreserved for future cycles.

Why PESA Rather Than Surgical Correction?
The key clinical decision point for men with obstructive azoospermia is whether to pursue surgical correction of the obstruction (e.g., vasectomy reversal) or sperm retrieval for ICSI. This decision is individualised and depends on the cause of obstruction, time since vasectomy (if applicable), female partner age, ovarian reserve, and couple preference. PESA+ICSI bypasses the obstruction entirely and provides a reliable route to biological parenthood when surgical reversal is not appropriate or desired.

• Outpatient procedure; patient returns home the same day
• No incision required (percutaneous = through the skin only)
• Combined with ICSI for fertilisation of oocytes
• 90–95% sperm retrieval success rate in confirmed OA
• Surplus sperm cryopreserved for future ICSI cycles (freeze-all strategy)

PESA is specifically indicated for obstructive azoospermia, distinguishable from non-obstructive azoospermia by preserved testicular function with a mechanical barrier to sperm egress. The most common etiologies include:

Post-Vasectomy Azoospermia (Most Common Indication Worldwide)
Vasectomy creates a deliberate mechanical block in the vas deferens. In men who later wish to father children, PESA retrieves sperm directly from the epididymis distal to the block. Sperm are found in 90–98% of post-vasectomy PESA attempts. The clinical decision between vasectomy reversal and PESA+ICSI involves weighing reversal patency rates (which decline after 10–15 years), the female partner's age and fertility, cost, and the couple's overall family-building goals.

Congenital Bilateral Absence of the Vas Deferens (CBAVD)
CBAVD results from failure of the Wolffian duct derivatives (vas deferens, seminal vesicles) to develop, caused in ~80% of cases by biallelic or monoallelic pathogenic variants in the CFTR gene. Men with CBAVD have normal spermatogenesis and normal testicular volume but no vas deferens on physical examination or scrotal ultrasound. PESA achieves sperm retrieval in 85–95% of CBAVD cases. Mandatory pre-treatment genetic counselling is required to assess offspring risk of cystic fibrosis.

Acquired Epididymal Obstruction
Epididymal scarring from prior sexually transmitted infections (chlamydia, gonorrhoea), epididymo-orchitis, or inadvertent ductal injury during inguinal hernia repair or scrotal surgery can cause obstructive azoospermia. PESA retrieval rates in acquired epididymal obstruction are 70–85%, slightly lower than post-vasectomy OA due to structural damage to epididymal tubules.

Ejaculatory Duct Obstruction (EDO)
Obstruction at the level of the ejaculatory ducts (from Mullerian duct cysts, calculi, or post-infectious fibrosis) typically presents with low-volume azoospermic ejaculate. Although transurethral resection of ejaculatory ducts (TURED) offers surgical correction, PESA+ICSI provides an alternative when TURED is not feasible.

• Post-vasectomy obstructive azoospermia
• CBAVD (congenital bilateral absence of vas deferens)
• Acquired epididymal obstruction (post-infective, post-traumatic, post-surgical)
• Ejaculatory duct obstruction
• Failed vasovasostomy or vasoepididymostomy

Correct patient selection is the single most important factor determining PESA success. A structured workup distinguishes obstructive from non-obstructive azoospermia and identifies any reversible or treatable underlying cause.

Confirming Azoospermia:
Azoospermia is diagnosed when two separate semen analyses (performed ≥4 weeks apart) show no sperm in the ejaculate, including after centrifugation of the entire specimen. Cryptozoospermia (rare sperm found only on centrifugation) requires separate clinical consideration and may not need surgical retrieval.

Hormonal Differentiation of OA vs NOA:
In obstructive azoospermia, spermatogenesis is intact. Therefore, FSH is normal or low (typically <7.6 IU/L) and inhibin B is normal or high (typically >80 pg/mL). In contrast, non-obstructive azoospermia (primary testicular failure) causes elevated FSH and suppressed inhibin B due to absent or severely impaired spermatogenesis. Testosterone and LH are measured to exclude hypogonadotrophic hypogonadism as a treatable cause before proceeding to retrieval.

Physical Examination:
Bilateral examination of the testes (volume, consistency), epididymides (fullness, tenderness), and vas deferens (presence/absence) is mandatory. Absent vas deferens on palpation is pathognomonic for CBAVD. Epididymal fullness and elongation suggest obstruction distal to a productive testis.

Scrotal Ultrasound (10–15 MHz):
High-resolution scrotal ultrasound confirms testicular echogenicity (normal in OA), measures testicular volume (≥12 mL expected in OA), identifies dilated epididymal tubules (characteristic of obstruction), and confirms the presence or absence of the vas deferens. It also excludes co-existing testicular pathology (varicocele, testicular microlithiasis, masses).

Genetic Testing:
All men with azoospermia should have karyotype (to exclude Klinefelter syndrome, 47 XXY) and Y-chromosome microdeletion analysis (AZFa, AZFb, AZFc deletions). Men with CBAVD require full CFTR mutation panel testing, as does their female partner before embryo transfer.

Female Partner Workup:
Anti-Mullerian hormone (AMH), antral follicle count (AFC), and age are assessed to determine ovarian reserve. Advanced female age (>38 years) or diminished ovarian reserve significantly affects IVF-ICSI success rates independently of sperm quality and must be discussed during counselling.

PESA technique has evolved since its original description. The following describes current best-practice technique and its integration with IVF-ICSI:

Anaesthesia Options:
The preferred approach is a spermatic cord block using 10–15 mL of 1% lidocaine (lignocaine) injected at the external inguinal ring under scrotal palpation guidance. Subcutaneous scrotal infiltration with 2–3 mL of 1% lidocaine at the puncture site supplements the cord block. Oral anxiolysis (diazepam 5–10 mg taken 30 minutes before) is offered for anxious patients. General or spinal anaesthesia is reserved for cases where simultaneous MESA or TESA is pre-planned as a backup.

Needle Selection — Technique Variation:
The standard approach uses a 23G butterfly needle attached via the butterfly tubing to a 20 mL syringe. Some operators prefer a 21G needle for faster aspiration flow in larger epididymides. The butterfly configuration allows the operator to control needle position with one hand while an assistant manages the syringe plunger. A few centres use a modified PESA needle set incorporating a three-way stopcock to allow flushing of the needle between aspiration passes.

Step-by-Step Procedure:

• The patient lies supine; the scrotum is cleaned with aqueous antiseptic and draped.
• The testicle and epididymis are fixed between the thumb and forefinger of the non-dominant hand, bringing the epididymal head to the anterior scrotal surface.
• The 23G butterfly needle is inserted through the scrotal skin into the epididymal caput (head) at a 45-degree angle.
• The syringe plunger is pulled to create negative pressure (5–10 mL of suction), and the needle is slowly oscillated while maintaining suction.
• Aspirated fluid (0.1–0.5 mL, often creamy or slightly turbid) is transferred to a specimen tube containing sperm wash medium and hand-carried immediately to the embryology laboratory.
• If no sperm are found, the needle is repositioned to the epididymal body or the procedure is repeated on the contralateral side.

Freeze-All Cryopreservation Strategy:
Any sperm retrieved beyond the immediate ICSI requirement are cryopreserved in liquid nitrogen in multiple small-volume straws (0.25–0.5 mL). The "freeze-all" strategy — in which all retrieved sperm are frozen and no fresh sperm are used — is increasingly adopted because it decouples the male and female components of the IVF cycle. This allows the female partner's endometrium to be optimised in a dedicated frozen embryo transfer (FET) cycle, which may improve implantation rates. Cryosurvival of PESA sperm is 50–70% for motile sperm, with fertilisation rates of 55–65% per injected oocyte using thawed sperm, comparable to fresh retrieval in most studies.

PESA has accumulated a robust evidence base since its introduction in 1994. Its clinical benefits are well-established across multiple patient populations and reproductive medicine programmes worldwide.

High and Reliable Retrieval Rate:
PESA achieves sperm retrieval in 90–95% of post-vasectomy patients and 85–95% of CBAVD patients when performed by an experienced operator. This high predictability allows couples to proceed with IVF cycle planning with confidence, minimising the distress and cost of cancelled cycles due to failed sperm retrieval.

Simplicity and Minimal Invasiveness:
The absence of surgical incision, operating microscope, and specialist microsurgical training requirements makes PESA far more widely accessible than MESA or MicroTESE. Patients experience minimal post-procedural morbidity — typically only mild scrotal tenderness and bruising for 2–5 days — and can return to light work within 24 hours.

ICSI Fertilisation and Pregnancy Outcomes:
When combined with ICSI, PESA sperm achieve fertilisation rates of 60–75% per injected oocyte. Clinical pregnancy rates per embryo transfer are largely determined by female age and embryo quality rather than the sperm retrieval method. In matched populations, PESA+ICSI live birth rates are comparable to those achieved using ejaculated sperm+ICSI. A systematic review by Esteves et al. (2013) documented clinical pregnancy rates of 28–42% per ICSI cycle using PESA sperm in OA patients, consistent with outcomes using ejaculated sperm in male factor infertility.

Banking for Multiple Cycles:
A single successful PESA session with adequate cryopreservation can support 3–5 or more subsequent ICSI cycles, dramatically improving the cost-efficiency of sperm retrieval over a couple's reproductive life. Banking also eliminates the risk of a failed retrieval on the day of oocyte collection, protecting the female partner from the physical and psychological burden of a cancelled cycle.

• Same-day outpatient procedure with immediate return home
• 90–95% success rate in obstructive azoospermia
• Fertilisation rates of 60–75% per ICSI oocyte
• Cryopreservation supports multiple future IVF cycles from a single retrieval
• Cost-effective compared to MESA or MicroTESE
• Repeatable if insufficient sperm retrieved at first attempt

PESA has a low overall complication rate, making it one of the safest sperm retrieval procedures. However, patients must be informed of the following:

Failed Sperm Retrieval (Procedure Failure):
PESA fails to retrieve viable sperm in 5–10% of OA cases and in the majority of NOA cases (where PESA is inappropriate as first-line). Procedure failure requires escalation to open surgical MESA or testicular biopsy/TESE. This eventuality must be discussed pre-procedurally, and a contingency plan agreed (e.g., simultaneous partner egg collection suspension, or proceed to testicular aspiration under the same anaesthetic).

Haematoma:
Scrotal haematoma is the most frequent complication (1–5%). Small haematomas resolve spontaneously with conservative management (scrotal support, NSAIDs, ice). Larger haematomas (>5 cm) may require surgical drainage and are more likely after multiple needle passes or in patients on anticoagulant therapy.

Epididymal Damage from Repeated Procedures:
Repeated PESA procedures at the same site carry a theoretical risk of epididymal scarring that may worsen the underlying obstruction. In practice, this risk is mitigated by cryopreserving adequate sperm at the first retrieval to avoid repeat procedures. When repeat PESA is required, a fresh site within the epididymis is targeted.

Infection:
Epididymo-orchitis following PESA occurs in <1% of cases with proper aseptic technique. Single-dose prophylactic antibiotics (oral ciprofloxacin 500 mg or co-amoxiclav 625 mg) are used in some centres, particularly in patients with a history of prior genital infection or immunosuppression.

Sperm Quality Considerations:
PESA sperm have reduced motility compared to ejaculated sperm. Only ICSI (not conventional IVF insemination) is appropriate. Fertilisation and embryo development are not compromised when ICSI is performed by an experienced embryologist.

Genetic Risk Transmission (CBAVD):
Children born after PESA+ICSI in CBAVD fathers have a 50% chance of inheriting the paternal CFTR mutation. If the mother is also a CFTR carrier, offspring risk of cystic fibrosis is 25%. Pre-implantation genetic testing for monogenic disorders (PGT-M) can screen embryos for CF mutations before transfer, but requires specialist genetics and IVF laboratory integration.

PESA is the first step in a coordinated IVF-ICSI treatment pathway. Post-procedure care involves both immediate recovery and longer-term integration with the couple's reproductive medicine plan.

Immediate Recovery (Day 0–3):
Patients are observed for 1–2 hours post-procedure and discharged when vitally stable and able to void. Scrotal support undergarment (or jockstrap) is worn for 48–72 hours. An ice pack applied for 20 minutes at a time on the day of the procedure reduces bruising and discomfort. Oral analgesia (paracetamol 1 g four times daily, with optional ibuprofen 400 mg three times daily if no contraindication) is prescribed for 3–5 days. Patients should avoid strenuous physical activity, heavy lifting, cycling, and sexual intercourse for 5–7 days.

Embryology Laboratory Report:
The embryologist provides a written procedure report including: total sperm found (motile, non-motile, immotile), motility grade (WHO 2021 criteria: progressive, non-progressive, immotile), number of vials cryopreserved, and an assessment of suitability for ICSI and future cycles. This report forms the basis of the IVF treatment plan.

Fresh vs Frozen-Thawed Sperm in ICSI:
If fresh PESA sperm are used, they must be coordinated with the female partner's oocyte collection. The male procedure is typically performed on the morning of egg retrieval. If the freeze-all strategy is adopted, partner oocyte collection and ICSI can proceed independently with thawed cryopreserved sperm, and embryo transfer takes place in a optimised frozen embryo transfer (FET) cycle 1–3 months later.

• Clinical review at 2 weeks if haematoma or significant pain persists beyond expected recovery
• Embryology team debrief on sperm quality and cryostorage report
• IVF team consultation to plan next cycle based on sperm bank status
• Annual review of cryostorage consent and extension (UK HFE Act requires periodic renewal)
• Genetic counselling follow-up for CBAVD patients before embryo transfer

Couples should be counselled that cumulative live birth rates across multiple IVF cycles (using banked PESA sperm) are substantially higher than single-cycle rates, and that persistence across cycles significantly improves the overall chance of achieving a live birth.

PESA is the most cost-effective surgical sperm retrieval procedure, but the total cost of achieving a live birth using PESA sperm includes the IVF-ICSI cycle, cryopreservation, and potentially multiple treatment attempts.

PESA Procedure Costs (2025–2026):

• UK (private): GBP 800–1,500 per session including embryology assessment. NHS funding for IVF (including retrieval) depends on CCG/ICB eligibility criteria (typically up to 3 NHS cycles if no previous children and female age <40).
• United States: USD 1,000–3,000 per PESA session. IVF cycle costs of USD 12,000–20,000 per cycle (including ICSI, embryo transfer, medications). PESA is typically charged separately from the IVF cycle fee.
• India: INR 15,000–40,000 for PESA session at ICMR-accredited ART clinics. Full IVF-ICSI cycle INR 1,20,000–2,50,000. India remains one of the most cost-accessible destinations for high-quality IVF treatment globally.
• Thailand: USD 500–1,200 for PESA. Full IVF-ICSI cycle USD 4,000–8,000 at internationally accredited fertility centres.

Cryopreservation and Storage:
Annual cryostorage fees are GBP 150–350 (UK) or USD 300–700 (US). UK HFE Act regulations currently allow storage for up to 55 years with periodic patient consent renewal. Organisations should check current local regulations as storage limits have been subject to legislative updates.

PESA vs Other Retrieval Methods — Cost Comparison:

• PESA: USD 1,000–3,000 — local anaesthesia, outpatient, no microscope
• MESA: USD 3,000–7,000 — general anaesthesia, operating microscope, higher sperm yield
• TESA: USD 1,000–2,500 — similar cost and setting to PESA; testicular not epididymal
• MicroTESE: USD 5,000–15,000 — operating theatre, general anaesthesia, reserved for NOA

For patients with confirmed obstructive azoospermia, PESA provides the optimal cost-benefit balance. Investing in adequate cryopreservation at first retrieval reduces future retrieval costs significantly.

Multiple sperm retrieval techniques exist, each with distinct indications, technical requirements, and clinical outcomes. Choosing the right technique requires careful clinical judgement based on the patient's diagnosis, anatomy, and reproductive goals.

MESA (Microsurgical Epididymal Sperm Aspiration)
MESA is performed under general anaesthesia using an operating microscope through a small scrotal incision. An epididymal tubule is identified and directly incised under magnification, yielding substantially larger numbers of motile sperm than PESA. MESA is preferred when: (1) PESA has previously failed to retrieve sufficient sperm; (2) the patient requires extensive sperm banking for many future IVF cycles; or (3) simultaneous microsurgical reconstruction is planned. MESA sperm survive cryopreservation with higher post-thaw motility than PESA sperm in some series, providing superior banking material. MESA has sperm retrieval rates of 95–100% in OA and is considered by some centres as the "gold standard" for obstructive cases when microsurgical expertise is available.

TESA (Testicular Sperm Aspiration)
TESA retrieves sperm from the testicular parenchyma using a needle passed directly into the testis. It yields seminiferous tubule fragments containing sperm and Sertoli cells. TESA is used when PESA fails in OA, or as a first-line retrieval in selected NOA patients. Sperm numbers and motility are typically lower than with epididymal aspiration, and ICSI fertilisation rates are slightly reduced. TESA is also performed as an outpatient procedure under local anaesthesia, at similar cost to PESA.

MicroTESE (Microsurgical Testicular Sperm Extraction)
MicroTESE is the gold standard for non-obstructive azoospermia (NOA). An operating microscope is used to systematically survey the testicular parenchyma and identify dilated, sperm-containing seminiferous tubules that are not visible macroscopically. Sperm retrieval rates in NOA range from 40–60%, dramatically higher than conventional TESE (20–40%) in the same population. MicroTESE is not indicated for obstructive azoospermia where PESA is simpler and equally effective.

Vasectomy Reversal (Vasovasostomy / Vasoepididymostomy)
Surgical reversal of vasectomy aims to restore natural patency. Vasovasostomy (vas-to-vas anastomosis) achieves patency rates of 85–97% when performed within 10 years of vasectomy, with natural pregnancy rates of 55–75%. When the interval exceeds 15 years, vasoepididymostomy (anastomosis to the epididymis) may be required, with lower patency rates of 30–60%. The key advantage of reversal is the potential for natural conception across multiple subsequent pregnancies without IVF costs. The disadvantage is surgical risk, recovery time (2–4 weeks), and declining success with time since vasectomy. PESA+ICSI is generally preferred when the female partner's age or ovarian reserve makes time to conception critical.

Electroejaculation and Spinal Vibrostimulation
For men with azoospermia due to spinal cord injury, retrograde ejaculation, or neurological conditions, penile vibratory stimulation or rectal electroejaculation under sedation can retrieve ejaculated sperm for ICSI without surgical epididymal or testicular access. These techniques are non-surgical alternatives specific to neurological and ejaculatory dysfunction rather than obstructive ductal disease.